Prevalence of Polypharmacy and Drug Interaction Among Hospitalized Patients: Opportunities and Responsabilities in Pharmaceutical Care - Zdravlje, medicina, lijecenje, zdravstveni portal

Prevalence of Polypharmacy and Drug Interaction Among Hospitalized Patients: Opportunities and Responsabilities in Pharmaceutical Care

Prevalence of Polypharmacy and Drug Interaction Among Hospitalized Patients: Opportunities and Responsabilities in Pharmaceutical Care
Edisa Trumic, Nurka Pranjic, Lejla Begic, Fahir Becic
Mat Soc Med. 2012; 24(2): 68-72

View PDF Fulltext

Abstract

Goal: Polypharmacy and drug-related problems (DRPs) have been shown to prevail in hospitalized patients. We evaluated the prevalence of polypharmacy; and investigated relationship between polypharmacy and: symptoms of DRPs, number of drugs and OTC, index of cumulative morbidity, length of exposure to polypharmacy and the number of days of hospital stay among hospitalized patients. Methodology: A study was performed in Pharmacies „Eufarm Edal“ Tuzla from 2010 to 2011. Polypharmacy was defined as using ≥ 3 drugs. The total study sample of 226 examiners were interviewed with special constructed questionnaires about DRPs. Experimental study group consisted of hospital patients with polypharmacy (n=166) and control group hospital patients without polypharmacy (n=60). Mann-Whitney test was used to test for significant self-reported symptom differences between groups and cross sectional subgroups, t- test and χ2- test for age, gender and treatment data in hospital. Results: The prevalence of polypharmacy was 74% among 226 hospitalized patients. The vulnerable age subgroup of hospitalized patients was men and hospitalized patients aged from 46 to 50 years (not geriatric patients). The prevalence of index of cumulative morbidity was 65%. The most common exposures varied by patient age and by hospital type, with various antibiotics, antidepressants, analgesics, sedatives, antihypertensives, flixotide, ranitidine and others. The prevalence of exposure to OTC and self- treatment was 80%. The prevalence of symptoms of drug-related problems were significantly differed among patients of experimental in relationship of control study group patients (P<0.001). Conclusion: In addition to helping to resolve the above mentioned issues, the results from this study could provide baseline information quantifying the problem of drug- related problems among hospitalized patients receiving polypharmacy and contribute to the formulation and implementation of risk management strategies for pharmacists and physicians in primary care health.

REFERENCES

1. Pranjić N. Medical error- professional liability for malpractice in Bosnia and Herzegovina. Liječ Vjesn. 2009; 131(7-8):229-232.

2. Alić A. Pranjić N, Ramić E. Polypharmacy and decreased cognitive abilities in elderly patients. Med Arh. 2011; 65(2): 102-105.

3. Hoigné R, Lawson DH, Weber E. Risk factors for adverse drug reactions – epidemiological approaches. Eur J Clin Pharmacol. 1990; 39: 321–325.

4. Hurwitz N. Predisposing factors in adverse reactions to drugs. BMJ. 1969; 1: 536–539.

5. Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol. 1981a; 20: 193–200.

6. Bergman U, Wiholm BE. Patient medication on admission to a medical clinic. Eur J Clin Pharmacol. 1981b; 20: 185–191.

7. Koh Y, Moldeen Kutty FB, Chuen L S. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag. 2005; 1(1): 39-48.

8. Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002; 24: 46–54.

9. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse drug events and negligence in hospitalized patients: results of Harvard Medical Practice Study I. N Engl J Med. 1991; 324: 370–376.

10. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277: 301–306.

11. Colt HG, Shapiro AP. Drug induced illness as a cause for admission to a community hospital. J Am Geriatr Soc. 1989; 37: 323–326.

12. Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol. 2000; 49: 158-167.

13. Green CF, Mottram DR, Rowe PH, et al. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Therap. 2000; 25: 355–361.

14. Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. Eur J Clin Pharmacol. 2011; 67(5): 507-519.

15. Feudtner C, Dai D, Hexem KR, et al. Prevalence of Polypharmacy Exposure Among Hospitalized Children in the United States. Arch Pediatr Adolesc Med. 2012; 166(1): 9-16.

16. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use. Ann Intern Med. 1992; 117: 634–640.

17. Lagnaoui R, Moore N, Fach J, et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol. 2000; 56 : 181–186.

18. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47: 533–543.

19. Nobili A, Licata G, Salerno F, Pasina L et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. Eur J Clin Pharmacol. 2011; 67(5): 507-519.

20. Viktil KK, Blix HS, Morger TA, et al. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol. 2007; 63(2): 187-195.

21. Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of Polypharmacy Exposure Among Hospitalized Children in the United States. Arch Pediatr Adolesc Med. 2012; 166(1): 9-16.

22. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. A Intern Med. 1991; 114: 956–966.

23. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997; 45: 945–948.

24. Lindquist M, Vigibase M. The WHO Global ICSR Database System: Basic facts. Drug Inform J. 2008; 42: 409-419.

25. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002; 324: 886-891.

26. Pranjić N. Social Pharmacy. Medical faculty University of Tuzla, PrintCOM, Tuzla 2011.

27. Rahman SZ, Khan RA. Environmental pharmacology: A new discipline. Indian J Pharmacol. 2006; 38 84): 229-230.

28. Van Mil. Pharmacy care, the future of pharmacy-theory, research and practice.Univeristy of Groningen, 2000.

29. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004; 291: 2243-2252.

30. Westin S. Heath I. Tresholds od normal blood pressure and serum cholesterol. BMJ. 2005; 330: 1461-1462.

31. Zarowitz BJ, Stebelsky LA, Muma BK, et al.Reduction of high risk of polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005; 25: 1636-1445.

Leave a reply

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>